Astellas and IBL to develop recombinant human protein made using transgenic silkworms

Published: 3-Jan-2014
Research & Development

Possibility of producing new medicines using this technology


Japanese pharmaceutical firm Astellas is to collaborate with Immuno-Biological Laboratories to develop pharmaceutical applications of recombinant human proteins made using transgenic silkworms.

The firms will examine and evaluate the production method and possibly develop new medicines.

IBL has developed a production system for the efficient secretion of soluble recombinant proteins in the cocoon of transgenic silkworms and has succeeded in the production of various useful proteins including antibodies and human collagen. The firm is actively progressing with the commercialisation of these proteins as raw materials for reagents in research, in vitro diagnostics, cosmetics and veterinary drugs.

  • Companies:
  • Astellas Pharma
See more

You may also like

Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Read more
Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Precise and efficient VARIO diaphragm pumps from Vacuubrand Advanced vacuum control for reproducible processes
  3. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  4. Bio-Courier: a new delivery technology to increase the global accessibility of RNA therapeutics Although lipid nanoparticles (LNPs) are a key delivery technology for nucleic acid therapeutics, their wider clinical translation is hindered by the recognised limitations of current manufacturing protocols
  5. Photocatalysed flow method accelerates synthesis of potent MC4R antagonist New automated continuous flow synthesis of spirocyclic tetrahydronaphthyridines for drug discovery

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Research & Development

Astellas invests $13m in cell and gene therapy innovation incubators

Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Research & Development

Astellas and Anokion to collaborate on immune tolerance therapeutics

The creation of a new company, Kanyos, will enable the preclinical development of products for type 1 diabetes and coeliac disease
Research & Development

Astellas and Potenza link up to build a portfolio of immuno-oncology therapeutics

Astellas takes an option to buy Potenza at the end of the collaboration period
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Syntheses that cut costs and boost yields

Reworking drug syntheses using cheaper or more environmentally friendly ingredients and catalysts can increase margins dramatically. Dr Sarah Houlton reports on recent successes
Subscribe now